Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 May 15;1-7.
doi: 10.1007/s11427-020-1732-2. Online ahead of print.

Low Dose of Hydroxychloroquine Reduces Fatality of Critically Ill Patients With COVID-19

Affiliations
Free PMC article

Low Dose of Hydroxychloroquine Reduces Fatality of Critically Ill Patients With COVID-19

Bo Yu et al. Sci China Life Sci. .
Free PMC article

Abstract

Coronavirus disease 2019 (COVID-19) is a pandemic with no specific drugs and high fatality. The most urgent need is to find effective treatments. We sought to determine whether hydroxychloroquine (HCQ) application may reduce the death risk of critically ill COVID-19 patients. In this retrospective study, we included 550 critically ill COVID-19 patients who need mechanical ventilation in Tongji Hospital, Wuhan, from February 1, 2020 to April 4, 2020. All 550 patients received comparable basic treatments including antiviral drugs and antibiotics, and 48 of them were treated with oral HCQ treatment (200 mg twice a day for 7-10 days) in addition to the basic treatments. Primary endpoint is fatality of patients, and inflammatory cytokine levels were compared between HCQ and non-hydroxychloroquine (NHCQ) treatments. We found that fatalities are 18.8% (9/48) in HCQ group, which is significantly lower than 47.4% (238/502) in the NHCQ group (P<0.001). The time of hospital stay before patient death is 15 (10-21) days and 8 (4-14) days for the HCQ and NHCQ groups, respectively (P<0.05). The levels of inflammatory cytokine IL-6 were significantly reduced from 22.2 (8.3-118.9) pg mL-1 at the beginning of the treatment to 5.2 (3.0-23.4) pg mL-1 (P<0.05) at the end of the treatment in the HCQ group but there is no change in the NHCQ group. These data demonstrate that addition of HCQ on top of the basic treatments is highly effective in reducing the fatality of critically ill patients of COVID-19 through attenuation of inflammatory cytokine storm. Therefore, HCQ should be prescribed as a part of treatment for critically ill COVID-19 patients, with possible outcome of saving lives. hydroxychloroquine, IL-6, mortalities, COVID-19.

Conflict of interest statement

The author(s) declare that they have no conflict of interest. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Similar articles

See all similar articles

References

    1. Al-Bari MAA. Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother. 2015;70:1608–1621. doi: 10.1093/jac/dkv018. - DOI - PubMed
    1. Bian X, Shi Z, Chen R, Cai J, Wang C, Xie J, Zhao L, Fei X, Zhang H, Tan Y, et al. Immunol Pathol. 2020. Aveolar macrophage activation and cytokine storm in the pathogenesis of severe COVID-19.
    1. Gautret, P., Lagier, J.C., Parola, P., Hoang, V.T., Meddeb, L., Mailhe, M., Doudier, B., Courjon, J., Giordanengo, V., Vieira, V.E., et al. (2020). Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Ag 20, 105949.
    1. Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, Labella A, Manson D, Kubin C, Barr RG, et al. N Engl J Med. 2020. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
    1. Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, et al. N Engl J Med. 2020. Compassionate use of remdesivir for patients with severe Covid-19.
Feedback